Overview
Oxytocin is a naturally occurring nine-amino acid peptide hormone produced in the hypothalamus and released by the posterior pituitary gland in mammals, including humans. It belongs to the neuropeptide category and plays a well-documented role in a wide range of physiological and neurological processes as observed in biological research. A synthetic version of oxytocin has been developed and is chemically identical to the naturally occurring form, making it a useful tool for laboratory and clinical research settings. Researchers have studied oxytocin in the context of social behavior, neurodevelopment, mood-related biological pathways, and the relationship between hormonal signaling and inflammatory processes. This peptide is intended strictly for research purposes and is not approved for human self-administration or personal use outside of medically supervised and regulatory-approved contexts.
Research & Bioactivity
Oxytocin is a neuropeptide that researchers have studied extensively in relation to social behavior, attachment, and neuropsychiatric processes. Studies have examined its potential role in modulating inflammatory pathways relevant to psychiatric conditions, with research investigating whether oxytocin's known anti-inflammatory properties may interact with treatment outcomes in clinical psychiatric settings. Research has also explored oxytocin's involvement in maternal bonding and mood regulation, including prospective longitudinal studies looking at the relationship between circulating oxytocin levels during pregnancy and the subsequent occurrence of postpartum depressive symptoms. In the context of neurodevelopment, researchers have investigated associations between early oxytocin exposure and offspring neurodevelopmental outcomes, including autism spectrum-related measures, using large-scale epidemiological datasets. Additionally, studies have examined oxytocin's influence on social memory and attachment cognition, with experimental research suggesting it may affect the emotional salience of recalled social experiences. Pharmacological research has also investigated dosing parameters for oxytocin in obstetric contexts, using sequential allocation models to characterize effective dose thresholds for uterine contractile response in both preterm and term gestational settings.
Published Research
Biological modulators of treatment outcome during psychiatric care: The interplay between inflammation and oxytocin.
Sedoff O, Brugnera A, Tasca GA, Maoz H, Bloch Y, et al. — 2026
BACKGROUND: Although scientific advancements highlight the involvement of inflammatory processes in psychiatric disorders, few studies have explored how these processes relate to treatment outcomes. This study aimed to examine whether inflammation is associated with reduced treatment outcomes in inpatient psychiatric care, and whether oxytocin (OT) - a neuropeptide known for its anti-inflammatory properties - may buffer these effects. METHODS: Patients (N = 72, 76% females) who received intranasal OT or placebo twice daily for four weeks adjacent to standard inpatient care were examined for their pre-treatment inflammation, using the neutrophil-to-lymphocyte ratio (NLR). Baseline Depressive symptoms, anxiety, suicidal ideation, and distress were assessed using self-report measures at pre and post-treatment. Multilevel models were utilized to test the predictive effects of baseline NLR on treatment outcomes and its interaction with OT administration. RESULTS: Higher pre-treatment NLR was associated with reduced improvement in trait anxiety (p = .02). A significant NLR × OT interaction emerged for depression (p = .005), indicating that OT administration did not significantly improve depression outcomes for patients with high baseline NLR (p = .35), but was associated with greater improvement among patients with low baseline NLR compared to placebo (p = .001). CONCLUSIONS: Inflammation is a potential biological factor shaping treatment outcome, however, OT administration benefits mostly those with low inflammation. Additional studies are needed to assess whether other anti-inflammatory agents may buffer its effects.
The role of serum oxytocin levels in the third trimester of pregnancy in the incidence of postpartum depressive symptoms.
Taghizadeh Z, Rezaei N, Khalesi ZB — 2026
Recent studies have explored the relationship between oxytocin and the risk of postpartum depression (PPD), yet the results have been inconsistent and require further investigation. As a result, this study examined the relationship between oxytocin and postpartum depressive symptoms. This research was a prospective longitudinal study performed et al.-Zahra Hospital (a tertiary facility located in Guilan province in Rasht) from January 2020 to August 2021. The data gathering tool included a demographic survey developed by the researcher and the Edinburgh Postnatal Depression Scale (EPDS), a self-report screening tool. Participants completed the demographic and Edinburgh questionnaires between 38 and 40 weeks, and venous blood samples were taken from them during this timeframe to evaluate oxytocin levels. The second assessment of postpartum depressive symptoms was conducted in the 6 to 8 weeks after giving birth. The average depression score during the third trimester of pregnancy was 10.51 ± 3.12. After delivery, the majority of the samples (n = 47, 59.5%) showed some degree of depressive symptoms. The average score for PPD was 11.9 ± 3.07. The Spearman's rank correlation coefficient was utilized to investigate the connection between serum oxytocin levels and the score achieved on the Edinburgh Postpartum Depression Scale. The results indicated that there was no correlation between third-trimester serum oxytocin levels and postpartum Edinburgh Postpartum Depression Scale (EPDS) scores. The results of this research indicated that serum oxytocin levels during the third trimester of pregnancy were not significantly linked to the postpartum depressive symptoms.
Association of intrapartum epidural analgesia and oxytocin exposure with offspring autism and neurodevelopment from the Japan Environment and Children's Study.
Tachi A, Takahashi Y, Ito Y, Kato S, Sugiura-Ogasawara M, et al. — 2026
Given the increasing prevalence of neurodevelopmental disorders, this study examined the association between autism and neurodevelopmental delays and exposure to intrapartum labor epidural analgesia (LEA) and synthetic oxytocin (OT) in offspring. The data were obtained from various questionnaires, including the Japanese Ages and Stages Questionnaires, Third Edition. Using data from a large-scale longitudinal birth cohort study in Japan, 72,801 participants were enrolled and follow-up to age 4 years. Exposure during labor was categorized into four groups: no-exposure, OT, LEA, and LEA-OT. Adjusted odds ratios for autism were 2.35 (95% CI 1.44-3.83) in the LEA-OT group and 2.41 (95% CI 1.31-4.45) in the LEA group. The E-values for the point estimates were 4.16 in the LEA-OT group and 4.29 in the LEA group, and those for the lower limits of the 95% confidence intervals were 2.39 and 2.05, respectively, indicating only moderate robustness to unmeasured confounding. Associations with autism were consistent across analyses in the LEA-OT group, but in sex-stratified analyses, only males showed an association. No consistent associations with neurodevelopmental delays were observed in any exposure groups. Since residual confounding cannot be excluded, with limited external validity, these findings warrant replication in independent cohorts to clarify causality.
Attachment, oxytocin, and maternal recollections: Further evidence for the salience hypothesis.
Shemirani M, Klein W, Nitschke JP, Krol SA, Sheldon S, et al. — 2026
Childhood memories featuring primary caregivers are the basis of attachment working models. Oxytocin plays a critical role in attachment bonding and social memory possibly by enhancing the emotional salience of social cues. Consistent with the salience hypothesis, prior work (in males) indicates that oxytocin administration positively biases recollections of maternal care and closeness for less anxious/more secure individuals but negatively biases such recollections for more anxiously attached individuals. We aimed to conceptually replicate and extend this work by probing oxytocin's effects on the emotional quality of attachment memories, and sampling males and females. Between 2013 and 2016, we recruited 77 participants and administered 24 international unit intranasal oxytocin/placebo (within-subject). Participants were presented with attachment-related cue words and, in response, recalled childhood memories of their mothers. We analyzed the emotionality of these memories using human raters and, in exploratory analyses, natural language processing software (Linguistic Inquiry and Word Count and Valence Aware Dictionary and Sentiment Reasoner). Replicating previous findings, human rater results revealed significant attachment anxiety by oxytocin interactions for negative emotionality ( = .031) and positive emotionality ( = .034), with more anxious participants reporting more negative and less positive emotional content following oxytocin (vs. placebo). The natural language processing analyses also showed significant attachment anxiety by oxytocin interactions for negative but not positive emotionality. Finally, we found no effect of attachment avoidance on emotionality, however, more avoidant individuals were less likely to emotionally self-disclose ( < .001), an effect that was potentiated by oxytocin ( = .05). This study supports the social-emotional salience hypothesis of oxytocin. (PsycInfo Database Record (c) 2026 APA, all rights reserved).
Minimum Effective Dose of Prophylactic Oxytocin Infusion During Cesarean Delivery in Preterm and Term Pregnancy: A Sequential Allocation Dose Finding Study.
Tyagi A, Singla S, Nigam C, Rautela RS, Malhotra RK, et al. — 2026
BACKGROUND: There is a paucity of uterine oxytocin receptors during preterm gestation. Whether this affects the requirement of oxytocin dose for uterine contraction in patients with preterm gestation is not researched. We compared effective dose in 90% of target population (ED90) of oxytocin infusion for satisfactory uterine tone during cesarean delivery in patients with preterm and term pregnancy. METHODS: This biased coin sequential allocation, dose finding study, with triple blinding to dose allocation included nonlaboring women >18 years posted for cesarean delivery under spinal block, into either term or preterm group (n = 30 each; completed or <37-week gestation, respectively). Oxytocin infusion was initiated at 13 IU·h-1 in the first patient in both groups. Dose in subsequent cases was determined by response to oxytocin in previous patient of a particular group (dosing interval = 2 IU·h-1). Uterine tone was assessed using the one-finger palpation method by the surgeon. Myometrial oxytocin receptor expression was also evaluated on tissue obtained during surgery, using immunohistochemistry (IHC). RESULTS: The ED90 of oxytocin infusion to prevent intraoperative uterine atony was 1.5 times greater in the preterm group (25.7 IU·h-1 [95% confidence interval {CI}, 16.4-35.1]) as compared to the term group (16.2 IU·h-1 [95% CI, 14.8-17.7]). Intraoperative oxytocin amount was significantly greater (14.3 [11.7-17.5] vs 12.8 [10.4-14.7] IU; P = .048), and the need of additional uterotonic was clinically higher (16% vs 10%; effect size = 0.5 [95% CI, 0.1-2.5]; P = .448) for the preterm group. IHC showed increased oxytocin receptor expression for term versus preterm group (P = .040). Incidence of oxytocin-associated hypotension was greater for preterm group (50% vs 13%; P = .002). CONCLUSIONS: During cesarean delivery, oxytocin requirement is almost 1.5 times greater for preterm as compared to term pregnancy. This was supported by decreased expression of the myometrial oxytocin receptor upon IHC.